Background-Blocking of glycoprotein VI-dependent pathways by interfering in vascular collagen sites is commonly seen as an attractive target for an antiplatelet therapy of acute atherosclerotic diseases such as myocardial infarction or stroke. Revacept (soluble dimeric glycoprotein VI-Fc fusion protein) has been shown to reduce platelet adhesion by blocking vascular collagen in plaques or erosion and to be safe in preclinical studies. A dose-escalating clinical phase I study was performed to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of Revacept in humans. Methods and Results-In a first-in-humans study, 30 healthy men received a single intravenous administration of 10, 20, 40, 80, or 160 mg Revacept. The serum concentration-time courses of each dosage of Revacept showed a narrow variation and a concentration and time dependence. Revacept did not significantly affect the bleeding time.
Clinical Perspective on p 1899
In recent years, a number of high-performing antiplatelet compounds have been developed that block thrombus formation and have been introduced successfully into the treatment of patients with myocardial infarction. Current antiplatelet agents have been shown to reduce ischemic events, but often at the expense of increased bleeding. [2] [3] [4] [5] These findings provide an important basis to study additional compounds with the potential to inhibit platelet adhesion and activation and collagen aggregation without affecting general hemostasis.
In contrast to existing drugs, which inhibit all platelets and therefore incur markedly increased risk of bleeding, compounds that specifically interfere in the collageninduced activation of platelets hold promise for reduced risk of complications. Revacept (PR-15, dimeric glycoprotein [GP] VI-Fc) has been found to have the same efficacy as known antiplatelet drugs, but did not incur any risk of bleeding complications in animal studies. 6 It is directed against collagen in endothelial lesions, and thereby scavenges the pivotal ligand for the activation of crucial platelet receptors. 7 Revacept potently inhibits collageninduced aggregation of human platelets ex vivo, 8 but not thrombin-or ADP-induced aggregation. Exposure of human blood to human plaque material from carotid endarterectomy ex vivo in a flow chamber resulted in relevant local platelet aggregation that was clearly inhibited by anti-GPVI (Glycoprotein VI) antibodies or GPVI downregulation 9 and Revacept. 10 In contrast to anti-GPVI antibodies, 11 however, Revacept neither induced downregulation of the platelet receptor nor reduced platelet count.
Here, we present the results of a clinical phase I study (EudraCT 2005-004656-12, NCT 01042964) that aimed to investigate the pharmacokinetic, pharmacodynamic, and safety parameters of Revacept in healthy male volunteers.
Methods
Revacept is a fusion protein consisting of the Fc part of human IgG1, a short hinge region derived of the same protein, a specific linker sequence, and the extracellular part of human GPVI. 6 This fully human fusion protein was expressed in Chinese hamster ovary cells. It was obtained as a covalently linked dimer of a molecular mass of 150 kDa as determined under nonreducing conditions by SDS-PAGE.
Revacept was produced by fermentation at Orpegen GmbH (now Glycotope-Biotech GmbH), Heidelberg, Germany, and manufactured at Evotec GmbH, Hamburg, Germany, and Glasgow, Scotland, according to good manufacturing practice guidelines.
Study Design
The trial, An Open Label Dose Escalating Safety and Pharmacokinetic Study of an Acute Intravenous Administration of PR-15, an Inhibitor of Platelet Adhesion, in Different Doses in Healthy Male Volunteers, was carried out at Medifacts GmbH (now ABX-CRO GmbH), Görlitz, Saxonia, Germany, from March 2006 through October 2007. It was granted approval by the local ethics board of Saxonia in 2004 (No. JU-EK-AMG-35/2004), and was amended in 2005 and 2006. The conception of the trial, drafting of the study protocol, supervision of the study, and interpretation of the analytic results were provided entirely by the predecessor company to Corimmun GmbH, Procorde GmbH, Martinsried, Germany, and its management and scientists and Dr Schlieper, Greifenberg, Germany, who served as a clinical research officer. After obtaining regulatory permission to start the trial, Procorde GmbH was merged with Trigen AG, Martinsried. The study was independently monitored by Dr W. Gielsdorf, Ulm, Germany, and regular audits were carried out by Dr P. Schlieper.
Initially, the trial was a randomized study. After the inclusion of the first 6 subjects, the trial was opened with approval of the ethics committee to an open-label dose-escalation study. The trial was conducted in accordance with International Conference on Harmonization guidelines for good clinical practice issued in July 1996 in accordance with the Declaration of Helsinki and with local laws and regulations. The trial was registered in the Eudra CT (Eudra CT 2005-004656-12) and clinical.trials.gov (NCT 01042964) databases.
Study Objectives
The primary objective was to evaluate the safety and tolerability of Revacept after a single intravenous dose by clinical assessment, laboratory parameters (hematology, blood chemistry and urinalysis, serology test, drug tests in urine), measurement of bleeding time, and evaluation of any possible antibody titers against Revacept. The online-only Data Supplement provides details on materials and methods.
The secondary objectives were to evaluate following the pharmacokinetic parameters: area under the serum concentration-time curve from time 0 to the last experimental time point (t) with a detectable drug concentration (C t ) that is greater than the limit of quantification [AUC (0-t) ]; area under the serum concentration-time curve from time 0 to infinity [AUC (0-ϱ) [, calculated as AUC (0-t) ϩC t /k el , where k el is the elimination rate constant estimated from a log linear regression plot of the terminal elimination phase comprising at least the last 3 observed serum concentrations; maximum observed concentration in plasma (C max ); time to C max (t max ); terminal half-life of the drug in serum (t 1/2 ) calculated as t 1/2ϭ ln2/k el ; total clearance of drug after intravenous administration, defined as the ratio of the dose level and AUC (0-ϱ) ; mean residence time, given as AUMC (0-ϱ) /AUC (0-ϱ) , where AUMC (0-ϱ) is the area under the first moment curve; and steady-state volume of distribution. For further details, please see the online-only Data Supplement.
Inclusion and Exclusion Criteria
Subjects meeting all of the following criteria were eligible for study participation: healthy, nonsmoking white men between 18 and 35 years of age who were normotensive (systolic blood pressure Յ140 mm Hg and diastolic blood pressure Յ90 mm Hg) with a body weight ranging from 75 to 85 kg. All subjects were tested and shown negative in assays searching for anti-HIV antibodies, HBs antigens, and hepatitis C virus. All gave written informed consent to study participation. The online-only Data Supplement provides further details.
Subjects
Thirty healthy men participated after providing written informed consent. Before inclusion in the study, the general health of the volunteers was ascertained by a detailed medical history, physical examination, ECG recording, and clinical chemistry tests. All subjects concluded the study according to the study protocol.
Drug Administration
The study medication was provided in solution in glass vials containing 40 mg that was prepared by the investigating physician to the respective dose in an infusion system and infused intravenously over 20 minutes. The trial medication was warmed to body temperature (37°C) just before dosing. Doses of Revacept were given as an infusion of 10, 20, 40, 80, or 160 mg to cohorts of 6 healthy men each. The study was initially started as randomized trial. Because the serum half-life of Revacept turned out to be longer than anticipated, the study protocol was modified by an addendum submitted to a vote by ethics boards. Thereafter, the study was conducted as an openlabel dose-escalation study starting with 10 mg. After completion of each dose group, a safety board discussed all findings before the next higher dose was administered to the subjects.
Adverse Events
Adverse events were monitored during the complete course of the study through investigator inquiries, spontaneous reports, and clinical evaluations, such as physical examinations, vital sign measurements, ECG (including 24-hour Holter monitoring), and clinical laboratory tests (eg, hematology, blood chemistry, coagulation, and urinalysis). For further details, please see the online-only Data Supplement.
Laboratory Parameters
In all subjects, drug safety was monitored by laboratory parameters before and after drug administration (see the online-only Data Supplement).
Additionally, on the evening of day 0, drug screening was carried out in urine. The Abuscreen test kit (Hoffmann-La Roche, Mannheim, Germany) was used to screen for amphetamines, methamphetamines, barbiturates, benzodiazepines, cocaine, opiates, tetrahydrocannabinol, and phencyclidine. An alcohol breath test was performed with a Dräger Alcotest 7410 PLUS. For further details, please see the online-only Data Supplement.
Bleeding Time and Platelet Aggregation
Bleeding time was measured via ear lobe incision (before and 3 hours after dosing) according to the Duke method.
Pharmacodynamics of Revacept was evaluated with platelet aggregation assays. The aggregation of human platelets was determined from samples of platelet-rich plasma after stimulation with collagen, prepared from rabbit aorta, ranging from 0.45 to 2.81 g/mL, ADP (20 mol/L), or thrombin receptor activating peptide (25 mol/L) for all samples in triplicate. The concentrations of thrombin receptor activating peptide and ADP were chosen in accordance with previous studies. 12, 13 Collagen-induced aggregation was titrated in each subject before drug administration to a minimum of 30% of the reference platelet-poor plasma sample, with adjusted collagen concentrations ranging from 0.45 to 2.81 g/mL. This collagen concentration was documented individually for each subject and then used throughout the whole course of the study. The online-only Data Supplement provides further details.
Preparation of Collagen From Rabbit Aorta
Rabbit collagen was isolated from freshly prepared aortic vessel walls; rabbit aortas from 7 healthy male New Zealand White rabbits (age, 14 weeks; body weight, 3 kg; source, Asamhof, Kissing, Germany) were used for preparation of a single batch, which was then used during the whole study (No. 30 -09-05; see the online-only Data Supplement). The stability of the frozen rabbit collagen was tested by analyzing its potency to stimulate platelet aggregation. The potency was unaltered over a period of 14 months.
Analysis of the Generation of Anti-Revacept Antibodies by ELISA
The generation of antidrug antibodies was excluded by subjecting serum samples derived from blood withdrawn 1, 22, and 43 days after drug administration by specific ELISA. The assays were performed at MDS Pharma (Allendorf, Switzerland) according to good laboratory practice principles. The online-only Data Supplement has additional details.
Determination of the Revacept Concentration in Human Serum by ELISA
For pharmacokinetic analyses, Revacept concentrations in human serum derived from blood withdrawals before and at distinct time points (5 minutes, 30 minutes, 1 hour, 4 hours, 12 hours, 24 hours, 72 hours, 120 hours, and 14 days) after drug administration were determined by ELISA. The analysis was performed by MDS Pharma Services (Allendorf, Switzerland) in accordance with the principles of good laboratory practice (see the online-only Data Supplement).
Statistical Methods
Data were presented by summary statistics as follows: number of observations, arithmetic mean, and SE or SEM as indicated. The normality assumption was tested by applying the Kolmogorov-Smirnov test to all samples. It was shown that all groups of data were normally distributed. Therefore, ANOVA followed by the Bonferroni analysis was used to test for significant differences between dosing groups and changes of aggregation values after Revacept administration at different time points with repeated measures ANOVA. For log-normal-distributed pharmacokinetic parameters, geometric means and geometric coefficients of variation were determined. For each dose level, pharmacokinetic parameters were determined by means of descriptive statistics. The linear regression for the correlations between Revacept doses and AUC was calculated with Excel software according to the ordinary least-squares regression line algorithm.
All adverse events were tabulated in full detail with respect to type, onset, duration, severity, and drug relation. Vital signs (blood pressure, pulse rate), 12-lead ECG, safety laboratory data, and antibody titers were evaluated by means of descriptive statistics.
Results
A total of 30 white men were divided into groups 1 through 5 (nϭ6 each) and received 10, 20, 40, 80, or 160 mg Revacept, respectively. All enrolled subjects completed the trial according to the study protocol. The demographic data revealed no significant differences with regard to weight, height, and body mass index, so the 5 dose groups were comparable (see Table 1 ). Incidentally, the ages of the 40-mg and 80-mg dose groups differed slightly.
Pharmacokinetics
The pharmacokinetics of each dosage of Revacept is shown in Figure 1 . It demonstrates a narrow variation and a concentration and time dependence. C max and AUC increased linearly with increasing dose (Figure 2 ). The t max stayed almost constant (because of intravenous administration of the medication). The elimination was slow; Revacept could still be detected 3 days after administration of the 10-mg dose (Ϸ0.5 g/mL) and higher. After 2 weeks, 1 g/mL could still be measured in the serum of those subjects who had received the 160-mg dose. The terminal half-life was lower in the 2 lower-dose groups than in the groups receiving 40, 80, and 160 mg, where a comparable half-life was determined. Correspondingly, the clearance was slow and the mean residence time high. The volume of distribution at steady state ranged between 7.8Ϯ2.7 and 12.3Ϯ2.8 L, suggesting that Revacept is confined primarily to the systemic circulation. All parameters are summarized in Table 2 .
General Hemostasis: Bleeding Time, Coagulation, and Platelet Count
Bleeding times as determined with the Duke method (earlobe incision) within each dose group were similar before and 3 hours after administration of Revacept. There were no significant differences between the 5 dose groups before and at 3 hours after Revacept infusion (Figure 3 ). We therefore concluded that Revacept did not have any significant effect on bleeding time.
There were no significant differences in platelet counts between the Revacept dose groups (Figure 4 ). Revacept also had no influence on general coagulation in the subjectsЈ blood as assessed by activated partial thromboplastin time and international normalized ratio in the dosing groups before and 3 days after Revacept administration ( Figure 5A and 5B ).
Platelet Aggregation: Pharmacodynamics
Measurements of maximum aggregation showed that there was a strong and clearly significant time-and dose-dependent inhibition of collagen-induced aggregation after Revacept administration in all dose groups ( Figure 6A ). The effect started at least 2 hours after infusion of Revacept, and remained up to 24 hours after higher doses (40, 80, and 160 mg). In the 40-mg dose group, the collagen-induced aggregation returned to baseline on day 22 (43.6Ϯ3.6%). In the 80and 160-mg dose groups, aggregation returned to normal on day 14 (44.7Ϯ9.2% and 32.9Ϯ4.9%, respectively). Revacept The 10 mg inhibited significantly weaker collagen-mediated aggregation compared with higher doses at 24 hours after drug application (PϽ0.0001). Moreover, 10 and 20 mg Revacept also inhibited significantly weaker collagenmediated aggregation (PϽ0.05) 7 days after drug administration compared with 40 or 160 mg Revacept. Thus, Revacept shows a certain dose effect with prolonged inhibition of collagen-mediated platelet aggregation at later time points after administration. In contrast, ADP-or thrombin receptor activating peptide-induced aggregation was not altered by administration of Revacept during the entire observation period ( Figure 6B and 6C ).
Safety Assessment
No serious adverse events were recorded during the complete duration of the study. There were 2 occurrences of mild to moderate intensity 4 and 20 days after the beginning of treatment. One subject showed symptoms of tonsillitis; the other subject exhibited symptoms of nasopharyngitis. The 2 subjects recovered, and the adverse events resolved without sequelae and were judged to be unrelated to treatment with the study drug.
There were some abnormal laboratory parameters (biochemistry and hematology) at screening, all of them not clinically relevant and evenly distributed among the different dosages. There was no trend toward a deterioration of any of these parameters in relation to Revacept. Systolic blood pressure values were all within the normal range. Four subjects (3 in the 20-mg group and 1 in the 160-mg group) showed abnormal changes in diastolic blood pressure at different time points. However, an effect of Revacept on diastolic blood pressure could not be derived from these results because 3 subjects showed a decrease and 1 subject showed an increase in diastolic blood pressure compared with screening values. No subject had a significant difference in diastolic blood pressure when data of measurements directly before and up to 48 hours after drug administration were compared.
Several subjects showed an abnormal change in pulse rate, defined as Ͼ20 bpm, after drug administration compared with pulse rate at screening. However, all of these subjects presented with differences in pulse rate directly before drug application compared with screening. There was no influence of Revacept on heart rate when pulse rates up to 48 hours after drug application were compared with those directly before drug application.
One subject in the 40-mg dose group had newly recognized incomplete right bundle-branch block in a 12-lead ECG 8 and 36 hours after drug administration. Two subjects had incomplete right bundle-branch block at screening and after drug administration. This finding was recorded as an abnormality by the investigators, but the pathological relevance of this finding is not clear and is a commonly seen variation in healthy young people. The other ECG parameters, such as P wave, PQ intervals, QRS complex, and QT intervals, were not significantly changed by the study medication.
The ECG measurements by 3-lead Holter monitoring showed no triplets, salves, atrial fibrillation, or paced beats during the observational period. Couplets, ventricular tachycardia, and pauses were seen only once in different dose groups and only at least 15 or 22 hours after drug application. No bigeminy, trigeminy, or artifacts were recorded during the observational period. Therefore, we conclude that there was no proarrhythmic effect of the drug.
The assay for anti-Revacept antibodies was negative in all samples assayed (assay sensitivity, 0.32 g/mL) 22 and 43 days after drug administration. 
Discussion
The clinical phase I study demonstrated that Revacept is a safe and well-tolerated new compound with a clear dosedependent pharmacokinetic profile and a dose-related, highly specific pharmacodynamic action. Revacept had no effect on general hemostasis, as determined by measuring bleeding times, or on coagulation, as determined by activated partial thromboplastin time and international normalized ratio. No anti-Revacept antibodies were detected up to 6 weeks after administration. The serum concentration initially decreased very rapidly, with a long-lasting remaining low concentration of Revacept. Collagen-induced platelet aggregation was dosedependently inhibited up to 7 days with prolonged inhibition of collagen-mediated platelet aggregation after higher dose levels. In contrast, ADP-or thrombin-(thrombin receptor activating peptide-) dependent platelet aggregation remained unaltered.
Despite progress in the understanding of the mechanisms of plaque-mediated arterial thrombosis, current antithrombotic concepts rely on the prevention of platelet aggregation by fibrinogen receptor antagonists, aspirin, and P 2 Y 12 antagonists. These concepts have the disadvantage of targeting the consequences, not the source, of the platelet activation and aggregation during acute vascular syndromes. Recent clinical data with intravenous fibrinogen receptor antagonists 14, 15 and novel antiplatelet drugs such as prasugrel 5 showed that improvements in the efficacy of platelet inhibition and the prevention of ischemic complications are often achieved at the expense of increased bleeding complications. Therefore, our aim was to focus on optimal safety in the search for a potent and safe agent to protect patients from arterial thrombosis. Glycoprotein VI has been considered a pivotal protein involved in platelet adhesion and tethering and in promoting the initial signaling cascade that leads to thrombus formation at sites of arterial injury or plaques (see elsewhere 1, 7 for a review). Glycoprotein VI has also been implicated in thrombus formation at human plaque material from carotid endarterectomy ex vivo, 9, 10 and GPVI-Fc/Revacept has been shown to bind to atherosclerotic plaques of humans and of different animal species. 8, 16 Moreover, in patients with acute coronary syndrome, 17, 18 transient ischemic attack, and stroke 19 platelet GPVI receptor expression is increased. Increased concentrations of soluble GPVI were found in the plasma of patients with atrial fibrillation and acute coronary syndrome. 20 Thus, GPVI seems to be an indicator or even a mediator of platelet activation and thrombus formation in clinical settings with atherothrombosis. Interestingly, in patients with high GPVI expression levels, basal platelet activity was significantly increased despite dual antiplatelet therapy. 18 Therefore, we aimed at inhibiting collagen as the most thrombogenic ligand of atherosclerotic plaques that initiates early stages of platelet activation to develop a safe antiplatelet agent to treat acute coronary syndrome, transient ischemic attack, and stroke. Revacept is the soluble, dimeric form of the GPVI receptor and binds to collagen and fibronectin at the atherosclerotic plaque ( Figure 7A ). 6, 16 The mechanism is illustrated in Figure 7B , which shows that Revacept, by binding to the atherosclerotic plaque, prevents platelet adhesion and consecutive thrombus formation at the site of vascular injury. Revacept thus prevents a very early step in acute vascular syndromes. Revacept was shown to inhibit local thrombus formation in a previous animal study. 6 The efficacy was similar to that of anti-GPVI antibodies studied in the same model, 21 which, however, induced markedly prolonged platelet inhibition as a result of internalization of GPVI and even platelet depletion in animals. 22 In several subjects who were identified with idiopathic thrombocytopenic purpura caused by anti-GPVI autoantibodies, low platelet counts were observed, together with a mild bleeding disorder. 23, 24 In contrast, no platelet depletion occurred after administration of Revacept in either the short or long term. Moreover, the efficacy of Revacept is increased compared with other GPVI-Fc fusion proteins, one of which showed efficacy only at clearly higher concentrations. 11 The present ex vivo results from healthy volunteers after Revacept administration showed dose-dependent inhibition of collagen-mediated platelet aggregation, with almost complete inhibition for 24 hours with a single dose of 20 mg and for up to 7 days with higher doses. Aggregation was normalized in all patients at the end of the observation protocol. Other GPVI interventions such as anti-GPVI antibodies, however, led to a moderate prolongation of bleeding time 21, 22 both with and without downregulation of GPVI expression on platelets 25 with 1 exception. 26 The combination of anti-GPVI antibodies with aspirin severely compromised hemostasis in mice, 27 which did not occur when Revacept was added to the same dose of acetylsalicylic acid in mice (unpublished results). Revacept specifically inhibits collagen-mediated platelet adhesion and aggregation and has no effect on ADP-and thrombin/ thrombin receptor activating peptide-mediated activation pathways. This shows another aspect of the specificity and therefore safety of the drug and its potential superiority to anti-GPVI antibodies, which also showed an additional inhibition of thrombin responses in platelets. 28 There was a pharmacokinetic-pharmacodynamic relationship; ie, the Revacept plasma concentration suppressed maximum collagen-induced aggregation starting 2 hours after Figure 7 . Revacept structure and mode of action. A, Schematic structure of Revacept as a dimeric Fc fusion protein with the IgG part and the extracellular domain of the human glycoprotein VI (GPVI) platelet receptor. B, Simplified model for platelet adhesion, aggregation, and activation in atherosclerotic vessels. Specific interaction of ligands in the endothelium and extracellular matrix of the subendothelium with various platelet receptors (top). Revacept binds to the ligands collagen (coll) and fibronectin (fn) in atherosclerotic stable or ruptured plaques. Revacept prevents the first steps of collagen-mediated platelet adhesion and the consecutive platelet aggregation, crosslinking, and platelet activation with consecutive release of procoagulant signals in acute arterial syndromes. drug administration that was significant 24 hours and 7 days after infusion at higher doses. The pharmacodynamic action persisted longer than anticipated from previous animal studies, which was probably due to the longer serum half-life of this fully human protein drug in men compared with that seen in the previous animal studies.
Therefore, the concept of lesion-directed inhibition of thrombus formation with Revacept seems a promising approach for the development of a safe and potent platelet inhibitor for the treatment of acute vascular syndromes. Moreover, long-term GPVI inhibition by Revacept seems to ameliorate atherosclerosis 8, 16 and has significant beneficial effects on the remodeling after catheter intervention in arteries. 29 Thus, a potent and safe anti-GPVI intervention with Revacept would impose beneficial effects on a broad range of atherothrombotic complications beyond the short-term application, which are currently only incompletely addressed by existing drugs in clinical routine.
